We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Moves -1.23%: What You Should Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 1.51% for the day. Meanwhile, the Dow lost 0.97%, and the Nasdaq, a tech-heavy index, lost 2.01%.
Shares of the vaccine maker have appreciated by 5.58% over the course of the past month, outperforming the Medical sector's loss of 7.54%, and the S&P 500's loss of 3.63%.
Market participants will be closely following the financial results of Novavax in its upcoming release. It is anticipated that the company will report an EPS of -$0.31, marking a 110.58% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $55.78 million, reflecting a 91.63% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.11 per share and revenue of $342.53 million, indicating changes of -104.26% and -69.51%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Novavax should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 47.68% higher. Right now, Novavax possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 144, finds itself in the bottom 42% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Stock Moves -1.23%: What You Should Know
Novavax (NVAX - Free Report) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 1.51% for the day. Meanwhile, the Dow lost 0.97%, and the Nasdaq, a tech-heavy index, lost 2.01%.
Shares of the vaccine maker have appreciated by 5.58% over the course of the past month, outperforming the Medical sector's loss of 7.54%, and the S&P 500's loss of 3.63%.
Market participants will be closely following the financial results of Novavax in its upcoming release. It is anticipated that the company will report an EPS of -$0.31, marking a 110.58% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $55.78 million, reflecting a 91.63% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.11 per share and revenue of $342.53 million, indicating changes of -104.26% and -69.51%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Novavax should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 47.68% higher. Right now, Novavax possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 144, finds itself in the bottom 42% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.